CORRECTION Open Access



Correction to: Visual imaging as a predictor of neurodegeneration in experimental autoimmune demyelination and multiple sclerosis

Gabrielle M. Mey¹, Kirsten S. Evonuk^{1,7}, McKenzie K. Chappell¹, Laura M. Wolfe¹, Rupesh Singh², Julia C. Batoki², Minzhong Yu^{2,3}, Neal S. Peachey^{2,3,4}, Bela Anand-Apte^{2,3}, Robert Bermel⁵, Daniel Ontaneda⁵, Kunio Nakamura⁶, Kedar R. Mahajan^{1,5} and Tara M. DeSilva^{1*}

Correction to: Acta Neuropathologica Communications (2022) 10:87

https://doi.org/10.1186/s40478-022-01391-y

Following publication of the original article [1], two missing sections were identified in the back matter of the article: the 'Author contributions' section and the 'Competing interests' section.

The statement in the 'Author contributions' section should read: GMM performed all EAE experiments and collected and analyzed IHC, IF, and EM data for all experiments, produced all figures from EAE data, and wrote manuscript draft. KSE assisted with initial EAE experiment and analyzed GFAP and Iba1 data in mouse thalamus. LMW and MKC assisted with cell counting and data analysis for CD3 and NeuN staining. RS, JCB, and BAA performed OCT imaging and analysis for rodent studies and contributed to the final revisions of the manuscript. MY and NSP recorded and analyzed VEPs from rodent studies and contributed to final revisions of the manuscript. RB, DO, and KN provided MS

The original article can be found online at https://doi.org/10.1186/s40478-022-01391-y.

Full list of author information is available at the end of the article

patient data as well as MRI imaging analysis and contributed to final manuscript revision. KRM performed analyses of human OCT, correlative analysis with MRI and neuroperformance measures, and contributed to conceptualization of research and writing of final manuscript. TMD conceptualized the research, oversaw all research, and wrote, revised, and edited the final manuscript. All authors read and approved the final manuscript.

The statement in the 'Competing interests' section should read: Dr. Robert Bermel discloses consultation for Astra Zeneca, Biogen, EMD Serono, Genzyme/ Sanofi, Genentech/Roche, LabCorp, Novartis, TG Therapeutics, and VielaBio. Dr. Robert Bermel also discloses research support from Biogen, Genentech, and Novartis, and shares rights to intellectual property underlying the Multiple Sclerosis Performance Test, currently licensed to Qr8 Health and Biogen. Dr. Daniel Ontaneda discloses research support from Genentech, Genzyme, and Novartis and consulting fees from Biogen Idec, Genentech/Roche, Genzyme, Janssen, Novartis, and Merck. Dr. Kunio Nakamura discloses personal compensation for licensing from Biogen and research support from Genzyme and Biogen. All other authors declare no competing interests.

The original article [1] has been updated.



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/oublicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

^{*}Correspondence: desilvt@ccf.org

¹ Department of Neurosciences, Lerner Research Institute, Cleveland Clinic Foundation, and Case Western Reserve University, 9500 Euclid Avenue, Cleveland, OH 44195, USA

Author details

¹Department of Neurosciences, Lerner Research Institute, Cleveland Clinic Foundation, and Case Western Reserve University, 9500 Euclid Avenue, Cleveland, OH 44195, USA. ²Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, OH, USA. ³Department of Ophthalmology, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA. ⁴Louis Stokes Cleveland VA Medical Center, Cleveland, OH, USA. ⁵Mellen Center for MS Treatment and Research, Neurological Institute, Cleveland Clinic Foundation, Cleveland, OH, USA. ⁶Department of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH, USA. ⁷Present Address: Hooke Laboratories, Inc., Lawrence, MA, USA.

Published online: 15 July 2022

Reference

 Mey GM et al (2022) Visual imaging as a predictor of neurodegeneration in experimental autoimmune demyelination and multiple sclerosis. Acta Neuropathol Commun 10:87. https://doi.org/10.1186/ s40478-022-01391-y

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- $\bullet\,$ thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

